Detalhe da pesquisa
1.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 389(24): 2256-2266, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870955
2.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 385(13): 1196-1206, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551229
3.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704501
4.
Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients.
Ophthalmology
; 129(6): 679-693, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35085662
5.
Treatment of Metastatic Melanoma in the Elderly.
Curr Oncol Rep
; 24(7): 825-833, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35316844
6.
A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
Radiology
; 293(1): 223-231, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31453767
7.
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Ann Surg Oncol
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38789613
8.
Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls.
Ophthalmology
; 125(2): 210-217, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28935400
9.
Melanoma Immunotherapy in the Elderly.
Curr Oncol Rep
; 20(2): 20, 2018 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500787
10.
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
Retina
; 38(6): 1063-1078, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29689030
11.
Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.
Front Mol Biosci
; 10: 1178382, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795219
12.
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
J Immunother Cancer
; 11(6)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37286303
13.
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).
Pigment Cell Melanoma Res
; 36(6): 542-556, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37804122
14.
Review of bi-specific therapies in uveal melanoma.
Cancer Gene Ther
; 29(12): 1814-1818, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236927
15.
Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases.
Saudi J Ophthalmol
; 36(3): 308-314, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36276251
16.
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
J Clin Oncol
; 40(17): 1939-1948, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254876
17.
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
Cancer Biother Radiopharm
; 37(1): 11-16, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021863
18.
Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases.
Front Oncol
; 12: 961517, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36212499
19.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
J Immunother Cancer
; 10(12)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600653
20.
Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Ocul Oncol Pathol
; 7(3): 168-176, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307327